Invasive Carcinoma

What the breach means

Breast tissue organises itself around a branching system of ducts and lobules, each lined with epithelial cells sitting on a basement membrane. That membrane is not merely anatomical furniture; it is the boundary the classification system turns on. Cells that have multiplied abnormally but remain inside it are carcinoma in situ — a separate category with its own behaviour and its own debate. The moment cells penetrate that membrane and enter the surrounding stroma, the diagnosis becomes invasive carcinoma, and virtually every clinical decision downstream shifts with it.

The shift matters because access to the stroma means access to blood vessels and lymphatics — the routes by which cancer cells can reach distant sites. That possibility does not make metastasis certain, and most people with small invasive tumours never develop it, but the biological potential is now present in a way it was not before. The staging systems built by organisations including the American Joint Committee on Cancer are structured around this: an in-situ lesion carries no T-stage risk of spread; once invasion is confirmed, tumour size, nodal involvement and distant spread all enter the calculation.

Types and their frequencies

The vast majority of invasive breast cancers — somewhere between seventy and eighty percent, according to WHO classification data — are invasive carcinoma of no special type (NST), formerly called invasive ductal carcinoma. The older name implied an origin in the large ducts, which is misleading; the current terminology is deliberately agnostic about site of origin. Invasive lobular carcinoma, the second most common category, accounts for roughly ten to fifteen percent of cases and tends to infiltrate in single-file columns of cells rather than forming a distinct mass, which makes it harder to detect mammographically and harder to measure pathologically.

Rarer special types — tubular, mucinous, medullary-like, cribriform, micropapillary among them — each have characteristic histological appearances and, in the case of tubular and mucinous carcinomas, generally more favourable outcomes. Grade and stage are assigned after histological examination of the excised tissue: grade describes how far the cells' appearance has deviated from normal, stage describes how far the disease has spread. The two axes are independent but together they drive most decisions about treatment intensity.

Receptors as targets

Confirming invasion is only the first step in pathological assessment. Every invasive carcinoma is now routinely tested for the oestrogen receptor, the progesterone receptor, and the protein HER2. These are not incidental details: they define which treatments the tumour is likely to respond to. An oestrogen-receptor-positive tumour can be attacked with agents that interfere with oestrogenic signalling — tamoxifen, or aromatase inhibitors — in ways that receptor-negative tumours cannot. The identification of the oestrogen receptor by Elwood Jensen in the 1960s at the University of Chicago was the conceptual foundation for this entire approach.

HER2-positive tumours, which before targeted therapy carried a worse prognosis, became treatable in a new way after trastuzumab was shown in randomised trials to improve survival in the late 1990s. The principle in both cases is the same: a molecular feature of the tumour, measurable on the tumour tissue, becomes both a predictor and a target. Tumours that lack all three markers — oestrogen receptor, progesterone receptor and HER2 — are classified as triple-negative, a category with a distinct epidemiology, a poorer short-term prognosis in aggregate, and no endocrine target to exploit.

The evidence base

What we know about the natural history of invasive carcinoma and the effect of treating it comes primarily from randomised controlled trials and from periodic meta-analyses that pool their results. The Early Breast Cancer Trialists' Collaborative Group, based in Oxford, has assembled individual patient data from trials worldwide since the 1980s, producing estimates of treatment effect more reliable than any single trial could generate. That exercise revealed, among other things, that systemic treatments — chemotherapy, hormonal therapy — reduce the risk of distant recurrence even in early-stage disease, confirming that the microscopic breach of a basement membrane, however small the primary tumour, has systemic implications that surgery alone cannot address.